You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs
|
|---|---|
| Published in |
Journal of Translational Medicine, January 2014
|
| DOI | 10.1186/1479-5876-12-13 |
| Pubmed ID | |
| Authors |
Pengfei Jiang, Rajesh Mukthavavam, Ying Chao, Ila Sri Bharati, Valentina Fogal, Sandra Pastorino, Xiuli Cong, Natsuko Nomura, Matt Gallagher, Taher Abbasi, Shireen Vali, Sandeep C Pingle, Milan Makale, Santosh Kesari |
| Abstract |
Glioblastoma (GBM) is a therapeutic challenge, associated with high mortality. More effective GBM therapeutic options are urgently needed. Hence, we screened a large multi-class drug panel comprising the NIH clinical collection (NCC) that includes 446 FDA-approved drugs, with the goal of identifying new GBM therapeutics for rapid entry into clinical trials for GBM. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | 20% |
| United States | 1 | 20% |
| Canada | 1 | 20% |
| Unknown | 2 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 157 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 1% |
| India | 1 | <1% |
| Netherlands | 1 | <1% |
| Singapore | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 151 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 36 | 23% |
| Student > Ph. D. Student | 28 | 18% |
| Student > Master | 22 | 14% |
| Student > Bachelor | 17 | 11% |
| Student > Doctoral Student | 11 | 7% |
| Other | 17 | 11% |
| Unknown | 26 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 36 | 23% |
| Biochemistry, Genetics and Molecular Biology | 27 | 17% |
| Medicine and Dentistry | 24 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 13 | 8% |
| Immunology and Microbiology | 5 | 3% |
| Other | 25 | 16% |
| Unknown | 27 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 November 2022.
All research outputs
#2,432,329
of 23,106,934 outputs
Outputs from Journal of Translational Medicine
#393
of 4,060 outputs
Outputs of similar age
#30,074
of 306,360 outputs
Outputs of similar age from Journal of Translational Medicine
#13
of 119 outputs
Altmetric has tracked 23,106,934 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,060 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 306,360 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 119 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.